Dai-ichi Life Holdings Stock (OTC: DLICY)

Latest news for Dai-ichi Life Holdings (OTC:DLICY) Stock

Dai-Ichi Life is Japan's second-largest life insurance company excluding recently privatized Japan Post Insurance, with a market share of slightly over 10%. Unlike its largest domestic competitors Nippon Life, Meiji Yasuda, and Sumitomo Life, which remain mutually owned by their policyholders, Dai-Ichi Life demutualized and listed on the Tokyo Stock Exchange in 2010. Its main domestic operating company accounts for around 60% of profits, its Frontier bancassurance subsidiary selling mainly savings products accounts for around 10%, Alabama-based Protective Life accounts for around 15%, TAL in Australia accounts for 7%, and Dai-Ichi Life Vietnam around 5%. Dai-Ichi also holds a 30% economic interest in Mizuho's Asset Management One.

DAI-ICHI LIFE HLDGS U/ADR by Dai-ichi Life Holdings, Inc.

Dai-ichi Life Holdings Inc

Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is in talks with major Hollywood studios to license more films for its Apple TV+ streaming service.
This move aims to expand its library and attract a larger audience by offering a mix of new and classic content.
Apple has approached several top studios to acquire more programming for its customers in the US and internationally, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-07-18/apple-is-in-talks-to-license-more-films-from-hollywood?sref=TBDibEcD" rel="noreferrer noopener">reports</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/03/37623644/apple-innovates-with-ai-ads-reportedly-tests-automated-placements-in-app-store-and-beyond" rel="noreferrer noopener">Apple Innovates with AI Ads, Reportedly Tests Automated Placements in App Store and Beyond</a>
Apple TV+ has primarily focused on original productions. Despite successes like &#8220;Ted Lasso&#8221; and &#8220;The Morning Show,&#8221; the platform has struggled to compete with giants like Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>).
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/18114501/newplot-42.png" alt="" class="wp-image-443573" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/18114501/newplot-42.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/18114501/newplot-42-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
To address this, Apple recently licensed about 50 movies, including classics like &#8220;Mean Girls&#8221; and &#8220;Titanic,&#8221; and is now looking to expand this effort.
With its extensive library, Netflix has one of the lowest cancellation rates, while Apple TV+ experiences higher churn. In addition to licensing more films, Apple aims to enhance its service by exploring new strategic partnerships.
Recent reports indicated that Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) is <a target="_blank" href="https://www.benzinga.com/news/24/07/39822614/disney-develops-tech-to-rival-netflix-and-boost-streaming-profits-report" rel="noreferrer noopener">focusing on increasing</a> &#8220;hours per subscriber&#8221; to enhance viewer engagement and compete with Netflix. Disney is working on personalized algorithms to recommend content.
Netflix had a market share of 22% in the second quarter of 2024, followed by Disney+ at 11% and Apple TV+ at 9%, as per <a target="_blank" href="https://www.statista.com/statistics/496011/usa-svod-to-tv-streaming-usage/" rel="noreferrer noopener">Statista</a>.
In May 2023, analyst Tim Long estimated that Apple TV+ contributed only 2% to Apple&#8217;s services revenue, Barron&#8217;s <a target="_blank" href="https://www.barrons.com/articles/apple-stock-price-tv-plus-earnings-34b3f10b" rel="noreferrer noopener">reports</a>. He projected that the streaming service would generate $1.5 billion in revenue in 2022, which would grow to $2.2 billion in 2023.
Needham analyst Laura Martin recently stated that <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39716606/apple-poised-for-revenue-boost-analyst-sees-advertising-as-key-growth-driver" rel="noreferrer noopener">selling CTV ads</a> exclusively on AppleTV+ could boost Apple&#8217;s revenue growth by 140 basis points, potentially doubling the current consensus growth rate of 1% for fiscal 2024.
Price Action:&nbsp;AAPL shares traded lower by 1.90% at $224.52 at the last check on Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock

News

Tech

Media

AAPL

NFLX

Apple TV+ Takes on Netflix with New Hollywood Licensing Deals

Mortgage rates continued to trickle down this month, falling to 6.77%. The housing market continues its long-term movement to equilibrium, albeit slowly, as housing remains <a href="https://www.benzinga.com/24/06/39536324/renters-need-to-make-66-000-a-year-to-afford-the-typical-apartment-can-they-buy-a-house-instead">unaffordable for many Americans</a>.
The Data: <a href="https://freddiemac.gcs-web.com/news-releases/news-release-details/mortgage-rates-continue-fall">According</a> to a Freddie Mac report, the average 30-year fixed mortgage rate fell to 6.77% in the week ending July 17.
This is lower than the 6.89% reading from the week ending July 11. It was 6.78% a year ago. The 30-year rates <a href="https://freddiemac.gcs-web.com/news-releases/news-release-details/mortgage-rates-continue-fall">hit</a> a relative peak of 7.79% in 2023.
Sam Khater, Freddie Mac&#8217;s chief economist, outlined Thursday&#8217;s report and its implications on the housing market.
"Mortgage rates are headed in the right direction and the economy remains resilient, two positive incremental signs for the housing market. However, homebuyers have yet to respond to lower rates, as purchase application demand is still roughly 5 percent below Spring when rates were approximately the same,&#8221; Khater said.
&#8220;This is not uncommon: sometimes as rates decline, demand weakens, and the apparent paradox is driven by buyers making sure rates don't decline further before they decide to purchase," Khater added.
A Redfin <a href="https://www.redfin.com/news/housing-market-update-housing-payments-mortgage-rates-decline/">report</a> from Thursday which quoted Chen Zhao, the company&#8217;s economic research lead, offered a note about interest rate expectations&#8217; impact on mortgage rates.
&#8220;Now that it's looking increasingly likely the Fed will cut interest rates by the end of the year, some house hunters believe mortgage rates will fall more and are waiting for that to happen before they buy," Zhao said. 
"But they may be waiting in vain; it's unlikely mortgage rates will drop much lower in the next few months, as markets are already pricing in the expectation of a rate cut in September, followed by several more at the end of 2024 and into 2025,&#8221; Zhao added.
<a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">According</a> to CME FedWatch, investors are pricing in two to three Federal Reserve rate cuts by the end of 2024. There is a 98% chance of a September rate cut, as <a href="https://www.benzinga.com/government/24/07/39696316/june-inflation-report-in-focus-could-it-seal-the-deal-for-september-rate-cut">CPI data shows</a> continued signs of inflation cooling.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/06/39464529/us-needs-1-5-million-more-homes-to-tame-record-prices">US Needs 1.5 Million More Homes To Tame Record Prices</a></li>
</ul>
Photo: Shutterstock

Economics

Real Estate

Mortgage Rates Continue To Tick Down In Mid-July: 'The Economy Remains Resilient'

Macquarie analyst Chad Beynon maintains DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Outperform and lowers the price target from $54 to $52.

Price Target

Analyst Ratings

DKNG

Macquarie Maintains Outperform on DraftKings, Lowers Price Target to $52

Macquarie maintains Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) with a Outperform and lowers the price target from $10 to $9.

GENI

Macquarie Maintains Outperform on Genius Sports, Lowers Price Target to $9

The Goldman Sachs Group, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) shares are trading lower today. Goldman Sachs Asset Management and Betterment jointly introduced the Goldman Sachs <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/n39840523/betterment-and-goldman-sachs-launch-industry-first-tax-smart-bonds-portfolio" rel="noreferrer noopener">Tax-Smart Bonds portfolio</a>.
Goldman Sachs has developed a strategy by combining short-duration U.S. Treasury bonds, high-quality corporate bonds, and municipal bond ETFs.
Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/39776059/goldman-sachs-targets-asias-fast-growing-economies-with-new-2b-private-equity-fund-report" rel="noreferrer noopener">Goldman Sachs Targets Asia&#8217;s Fast-Growing Economies With New $2B Private Equity Fund: Report</a>
This portfolio leverages Goldman Sachs&#8217; expertise in bond markets and Betterment&#8217;s automation.&nbsp;
The Goldman Sachs Tax-Smart Bonds portfolio is tailored for clients in higher tax brackets seeking a lower-risk bond strategy compared to equities.
This approach adapts to both longer-term trends and current market conditions, ensuring flexibility to respond to events such as the COVID-19 pandemic and U.S. debt ceiling debates, which can impact market stability.
Padideh Raphael, Global Head of Third Party Wealth at Goldman Sachs Asset Management, said, &#8220;It is important for investors seeking to create and safeguard long-term wealth to consider after-tax returns in their portfolios.&#8221;&nbsp;
&#8220;This latest collaboration, combining Goldman Sachs&#8217;s investment capabilities with Betterment&#8217;s innovative technology platform and customer-first approach, will allow us to work together on behalf of clients who seek attractive after-tax bond yields.&#8221;
This week, the bank reported second-quarter revenue of&nbsp;$12.730 billion, beating the consensus of&nbsp;$12.456 billion and EPS of&nbsp;$8.62,&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39769910/goldman-sachs-q2-earnings-revenue-and-eps-beat-investment-banking-fees-up-21-hikes-dividend" rel="noreferrer noopener">beating the consensus of&nbsp;$8.35</a>.
Related: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39801120/goldman-sachs-analysts-boost-their-forecasts-following-better-than-expected-earnings" rel="noreferrer noopener">Goldman Sachs Analysts Boost Their Forecasts Following Better-Than-Expected Earnings</a>
Investors can gain exposure to the stock via&nbsp;IShares U.S. Broker-Dealers &amp; Securities Exchanges ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAI#NYSE">IAI</a>) and&nbsp;Invesco KBW Bank ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBWB#NASDAQ">KBWB</a>).
Price Action: GS shares are down 2.30% at $490.63 at the last check Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Shutterstock

Equities

Large Cap

Contracts

iShares Dow Jones US Broker Dealers Index Fund

KBWB

Goldman Sachs and Betterment Launch Tax-Smart Bonds Portfolio for Savvy Investors: Details

RB Global's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBA#NYSE">RBA</a>) short percent of float has risen 91.03% since its last report. The company recently reported that it has 9.56 million shares sold short, which is 5.96% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.92 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>RB Global Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721323821_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for RB Global has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing RB Global's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, RB Global's peer group average for short interest as a percentage of float is 3.99%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into RB Global's Recent Short Interest

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 20 years by 12.59% on an annualized basis producing an average annual return of 21.02%. Currently, Alnylam Pharmaceuticals has a market capitalization of $29.88 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $4,144.21 today based on a price of $236.22 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721323820_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALNY

$100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today

Boise Cascade's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCC#NYSE">BCC</a>) short percent of float has fallen 5.15% since its last report. The company recently reported that it has 988 thousand shares sold short, which is 3.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.01 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Boise Cascade Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721323816_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Boise Cascade has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Boise Cascade's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Boise Cascade's peer group average for short interest as a percentage of float is 4.19%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(BCC) - Analyzing Boise Cascade's Short Interest

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 6.31% on an annualized basis producing an average annual return of 17.12%. Currently, Danaher has a market capitalization of $182.69 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $484.36 today based on a price of $246.65 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721323814_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Danaher 10 Years Ago Would Be Worth This Much Today

Belden's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>) short percent of float has fallen 7.1% since its last report. The company recently reported that it has 1.00 million shares sold short, which is 3.27% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.41 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Belden Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721323811_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Belden has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Belden's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Belden's peer group average for short interest as a percentage of float is 4.12%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Belden?

Imagine waking up after being frozen for decades, only to discover you&#8217;re broke. That&#8217;s a nightmare nobody wants, especially the rich. Making sure their wealth lasts is easier than reversing death, though.&nbsp;
Cryonics, or freezing the body after death in hopes of future revival, is attracting serious attention. According to Bloomberg Law, estate lawyers are developing "revival trusts" to keep wealth intact for those who opt for cryopreservation.
Don't Miss:
<ul>
<li>Amid the ongoing EV revolution, previously overlooked low-income communities<a href="https://www.benzinga.com/money/dunamis-1"> now harbor a huge investment opportunity at just $500.</a></li>
<li>General Motors and other leaders revealed to be<a href="https://www.benzinga.com/money/energyx"> investing in this revolutionary lithium start-up — allowing easy entry by launching at just $9.50 per share.</a></li>
</ul>
Once considered a crazy idea, it is now somewhat trendy. Alcor Life Extension Foundation, one of the largest cryonics facilities, has about 5,500 people planning to be frozen, and some estate lawyers have already helped hundreds of people set up revival trusts to preserve their wealth until they can be revived.
Revival trusts are based on some big assumptions but are taken seriously enough to be discussed at industry conferences. These trusts differ from dynasty trusts because they aim to benefit the revived person. Across the country, the laws are already changing to allow trusts to last for centuries, with some states like Florida permitting trusts to continue for up to 1,000 years.
Despite uncertainties, the quest for immortality through cryonics is gaining traction. According to Business Insider, tech billionaires like Peter Thiel, Sam Altman, and Jeff Bezos invest heavily in anti-aging and cryonics research.&nbsp;
Trending: Rory McIlroy&#8217;s mansion in Florida is worth $22 million today, doubling from 2017 —<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> here&#8217;s how to get started investing in real estate with just $100</a>
<a href="https://www.benzinga.com/news/23/05/32237133/peter-thiel-wants-to-conquer-death-with-cryogenic-preservation-we-havent-even-tried">Thiel plans to be cryogenically preserved</a>, viewing it as an ideological statement. He believes humanity should "either conquer death or at least figure out why it&#8217;s impossible."
<a href="https://www.benzinga.com/news/23/03/31347122/openai-ceo-sam-altman-funds-longevity-startup-with-goal-to-increase-human-lifespan-by-10-years">Altman has invested $180 million in Retro Biosciences</a>, a startup that aims to extend healthy human life spans. Bezos has invested in Altos Labs, a startup that is developing therapies to stop or reverse aging.&nbsp;
The quest to cheat death is becoming more mainstream. Take Bryan Johnson, a tech executive known for his ambitious anti-aging efforts. Johnson reportedly spends $2 million a year on his anti-aging regimen. This includes taking 111 pills daily, eating all his food within a strict time frame between 6 a.m. and 11 a.m., and employing a light therapy mask. At one point, he even <a href="https://www.youtube.com/watch?v=8l3nfzEYSwI&amp;pp=ygUrYmxvb2QgcGxhc21hIGluZnVzaW9ucyBmcm9tIGhpcyB0ZWVuYWdlIHNvbg%3D%3D">received blood plasma infusions</a> from his teenage son, although he stopped this practice due to a lack of evidence supporting its benefits.
See Also: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
HBO&#8217;s docuseries How To with John Wilson explored cryopreservation in its final episode, offering a glimpse into this strange and futuristic world. The show stressed that it&#8217;s not just the wealthy interested in cryonics; many regular people are drawn to the idea, dreaming of a futuristic world or simply wanting to witness future progress.
Still, cryonics is expensive. Too expensive for the common folk. Alcor, for example, <a href="https://www.benzinga.com/news/23/09/34922511/chasing-immortality-a-chilling-reality-why-more-and-more-people-plan-to-freeze-their-brains-bodies-u">charges $80,000 to freeze a head</a> and $200,000 for a whole body, plus annual dues. Most members pay for this by naming Alcor as their life insurance beneficiary.&nbsp;
Despite the high costs and uncertainties, people who hope for a second chance at life continue to invest in cryonics and revival trusts.
The pursuit of longevity and reversing aging is often driven by the belief that aging is a disease that science can eventually cure. While the technology to fully overcome aging isn&#8217;t available yet, cryonics offers a hopeful bridge to that future.&nbsp;
Read Next:
<ul>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield.</a></li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a></li>
</ul>

Startups

Back From The Dead And Broke? Not For The Wealthy — 5,500 Betting On Cryonics: Ensuring Wealth Beyond The Grave

JMP Securities analyst Aaron Hecht reiterates Marriott Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAC#NYSE">VAC</a>) with a Market Outperform and maintains $115 price target.

Reiteration

JMP Securities Reiterates Market Outperform on Marriott Vacations, Maintains $115 Price Target

JMP Securities analyst David Scharf reiterates Synchrony Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) with a Market Outperform and maintains $60 price target.

JMP Securities Reiterates Market Outperform on Synchrony Finl, Maintains $60 Price Target

WIIM

Abbott Laboratories shares are trading lower. The company reported Q2 financial results.

D.R. Horton, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) shares are trading higher after the company reported&nbsp;<a target="_blank" href="https://benzinga.com/pressreleases/24/07/b39833823/d-r-horton-inc-americas-builder-reports-fiscal-2024-third-quarter-earnings-and-declares-quarterly-" rel="noreferrer noopener">third-quarter&nbsp;FY24 results</a>.
Sales grew&nbsp;2%&nbsp;Y/Y to&nbsp;$10.0 billion, beating the consensus of&nbsp;$9.77 billion. Net sales orders increased 1% Y/Y to 23,001 homes and&nbsp;were flat in value at $8.7 billion.
Homes closed in the quarter increased 5% Y/Y to 24,155 homes and 6% in value to $9.2 billion.
Sales order backlog of homes under contract as of June 30, 2024, decreased&nbsp;12%&nbsp;to 16,792 homes and&nbsp;12%&nbsp;in value to&nbsp;$6.6 billion.
D.R. Horton had 42,600 homes in inventory, of which 26,200 were unsold as of June-end.
EPS was&nbsp;$4.10&nbsp;(+5%&nbsp;Y/Y),&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of&nbsp;$3.78.</a>
Return on equity (ROE) was&nbsp;21.5%&nbsp;for the trailing twelve months ended June 30, 2024, and homebuilding return on inventory (ROI) was&nbsp;29.5%.
The company&#8217;s net cash used in operations for the nine months totaled&nbsp;$228.2&nbsp;million. Consolidated cash balance was&nbsp;$3.0 billion, and available capacity on its credit facilities was&nbsp;$2.8 billion, for a total liquidity of&nbsp;$5.8 billion.
Buyback: D.R. Horton repurchased 3.0 million shares of common stock for&nbsp;$441.4 million&nbsp;during the quarter. The company&#8217;s remaining stock repurchase authorization on June 30 was&nbsp;$459.7 million.
In July 2024, the Board of Directors authorized a new stock repurchase program of up to $4.0 billion, replacing the previous authorization. This new authorization has no expiration date.
Dividend: Subsequent to quarter end, D.R. Horton declared a quarterly dividend per share of $0.30, payable on August 8 to stockholders of record on August 1.
FY24 Outlook: D.R. Horton revised&nbsp;the outlook&nbsp;for revenue to&nbsp;$36.8 billion-$37.2 billion (from $36.7 billion&nbsp;to&nbsp;$37.7 billion) vs. the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus of&nbsp;$36.972 billion</a>.
It now expects homes closed to be 90,000 to 90,500 (prior view<a target="_blank" href="https://www.benzinga.com//node/38315651" rel="noreferrer noopener"> 89,000 to 91,000 homes</a>).
DHI reiterated cash provided by operations&nbsp;guidance&nbsp;of around&nbsp;$3.0 billion&nbsp;and currently expects share repurchases of ~$1.8 billion.
David Auld, Executive Chairman, said, &#8220;Although inflation and mortgage interest rates remain elevated, the supply of both new and existing homes at affordable price points is still limited, and demographics supporting housing demand continue to be favorable.&#8221;
Investors can gain exposure to the stock via&nbsp;IShares U.S. Home Construction ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITB#BATS">ITB</a>) and&nbsp;SMI 3Fourteen Full-Cycle Trend ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCTE#NASDAQ">FCTE</a>).
Price Action: DHI shares are up 6.2% at $167.15 at the last check Thursday.
Image via Shutterstock

Earnings

Guidance

Dividends

Buybacks

Movers

FCTE

iShares Dow Jones US Homenstruction Index Fund

Builder D.R. Horton Beats On Q3 Earnings, Authorizes $4B Stock Buyback, Tightens FY24 Home Sales Forecast & More

A new study reveals how psilocybin, a compound in <a href="https://www.benzinga.com/topic/magic-mushrooms">magic mushrooms</a> induces dynamic hyperconnectivity in the brain, leading to profound ego-modifying experiences and feelings of oceanic boundlessness. Published in <a href="https://www.sciencedirect.com/science/article/abs/pii/S2451902224000843?via%3Dihub">Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</a>, this research delves into the mystical experiences reported by users, highlighting the therapeutic potential of psychedelics for treating psychiatric disorders.
<h4 class="wp-block-heading">Understanding Oceanic Boundlessness</h4>
The concept of oceanic boundlessness, often described as a sense of unity, blissfulness, insightfulness and spiritual experience, is frequently associated with psychedelic sessions. The study, one of the first to utilize brain imaging in psychedelic research, identifies a specific link between the psychedelic state and changes in dynamic brain connectivity. Unlike previous research showing static <a href="https://www.benzinga.com/markets/cannabis/22/04/26592568/psilocybin-more-effective-than-antidepressants-in-treating-depression-new-study-shows">increases in global brain connectivity under psychedelics</a>, this study demonstrates that hyperconnectivity is dynamic, correlating with the feeling of oceanic boundlessness.
<h4 class="wp-block-heading">Psilocybin&#8217;s Impact on Brain Function</h4>
Johannes G. Ramaekers, PhD, from Maastricht University, notes that psilocybin has shown potential in treating a variety of disorders, including OCD, anxiety, depression and addiction. &#8220;What was not fully understood is what brain activity is associated with these profound experiences,&#8221; Ramaekers explains. The brain&#8217;s tendency to enter a hyperconnected-hyperarousal pattern under psilocybin suggests a potential for variant mental perspectives. This study sheds light on the interplay between brain dynamics and subjective experiences, offering new insights into the neurophysiology of the psychedelic state.
<h4 class="wp-block-heading">Detailed Study Findings</h4>
The research analyzed fMRI data from two groups: one received psilocybin, the other a placebo. Participants on psilocybin reported significant phenomenological changes with brain connectivity analysis revealing global region-to-region connectivity patterns. This hyperconnected pattern explains the variant mental associations experienced by participants and links to oceanic boundlessness and unity.
Larry Fort, a PhD candidate at the University of Liège, emphasizes the ego-modifying (&#8220;egotropic&#8221;) effects of psilocybin. &#8220;We expected that the hallucinatory dimensions of experience would correlate the highest with psilocybin&#8217;s hyperconnected pattern,&#8221; Fort says. However, the study found a stronger correlation between ego-modifying experiences and hyperconnectivity than with hallucinatory experiences.
<h4 class="wp-block-heading">Future Implications for Psychedelic Therapy</h4>
Cameron S. Carter, MD, editor-in-chief of &#8220;Biological Psychiatry: Cognitive Neuroscience and Neuroimaging,&#8221; says the study provides new insights into the neurophysiological mechanisms underlying psilocybin&#8217;s effects. &#8220;It sets the stage for future studies using other psychedelic agents to examine whether the dynamic connectivity effects reflect a general mechanism for the therapeutic effects of these compounds.&#8221;
Athena Demertzi, PhD, from the University of Liège, adds that the brain&#8217;s hyperconnected regions showed lower global signal amplitude, approximating heightened cortical arousal. &#8220;This might be an important correlation as we move towards a full characterization of brain states under psychedelics,&#8221; she explains.

Cannabis

Psychedelics

First-Of-Its-Kind Imaging Study Links Psilocybin To Dynamic Brain Hyperconnectivity

Macro Economic Events

Politics

General

Nancy Pelosi Denies Earlier Reports, Aide Says "Sadly, The Feeding Frenzy From The Press Based On Anonymous Sources Misrepresents Any Conversations The Speaker May Have Had With The President."

Shares of Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) fell sharply during Thursday's session after the company reported <a href="https://www.benzinga.com/news/earnings/24/07/39834307/dominos-pizza-suspends-1-100-global-net-store-outlook-after-q2-earnings-stock-tumbles">mixed quarterly results.</a>
The company reported second-quarter FY24 sales growth of 7.1% year-on-year to $1.097 billion, missing the analyst consensus estimate of $1.103 billion.
The company is temporarily suspending its guidance metric of 1,100+ global net stores growth until the full effect of DPE's store opens and closures on international net store growth are known.
Domino&#8217;s Pizza shares dipped 11.2% to $420.36 on Thursday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Onconetix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) climbed 97.6% to $0.2944. On July 15, Onconetix announced closing of warrant exercise for $1.11 million gross proceeds.</li>
<li>Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) jumped 71.6% to $3.86. Silo Pharma said it has entered into a Device and CMC Development Master Plan with Resyca BV, a medical technology provider.</li>
<li>Chuy&#8217;s Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHUY#NASDAQ">CHUY</a>) rose 47.6% to $37.29 after the company and Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) jointly announced that Darden will acquire Chuy's Holdings.</li>
<li>JE Cleantech Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCSE#NASDAQ">JCSE</a>) jumped 24.8% to $0.8873.</li>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) gained 19% to $2.0407. Amphenol announced plans to acquire mobile networks businesses from CommScope.</li>
<li>LivePerson, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPSN#NASDAQ">LPSN</a>) gained 18% to $1.1500. LivePerson is expected to release its second quarter financial results after the closing bell on Wednesday, July 31.</li>
<li>Kopin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOPN#NASDAQ">KOPN</a>) rose 16% to $1.32. Kopin said it has achieved production approval milestone on next generation F-35 OLEDoS Microdisplay.</li>
<li>NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) surged 15.3% to $1.08 after the company announced it will present new SNK01 biomarker data at the Alzheimer&#8217;s Association International Conference.</li>
<li>ZimVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) gained 14.7% to $21.74.</li>
<li>Virtu Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>) rose 13.2% to $26.61 after the company reported better-than-expected second-quarter financial results.</li>
<li>Acurx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) rose 10.7% to $2.90.</li>
<li>D.R. Horton, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) shares rose 10.6% to $174.29 after the company reported better-than-expected third-quarter financial results and revised its FY24 guidance. Also, the company authorized a new $4 billion share repurchase.</li>
<li>Canadian Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) gained 8.3% to $17.89.</li>
<li>Infosys Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFY#NYSE">INFY</a>) rose 7.4% to $22.07 as the company reported first-quarter revenue growth of 2.5% in constant currency terms year-on-year to $4.71 billion, beating the analyst consensus estimate of $4.65 billion.</li>
<li>Ostin Technology Group Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares climbed 7.1% to $0.2944.</li>
<li>Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) gained 6% to $135.83 in sympathy with D.R. Horton, which reported better-than-expected third-quarter financial results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Agenus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) shares fell 52.7% to $8.36 after the company announced the FDA discouraged an accelerated approval pathway at the end-of-Phase 2 meeting.</li>
<li>Leslie&#8217;s, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) fell 30.7% to $2.83 after the company reported preliminary financial results for the third quarter and cut its full-year guidance. Multiple analysts also lowered price targets on the stock Thursday morning.</li>
<li>Alaunos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) fell 26% to $4.57. Alaunos Therapeutics announced a reverse stock split of 1-for-10, effective July 18.</li>
<li>Aptevo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares fell 23% to $0.4471 after jumping 76% on Wednesday. On July 1, Aptevo Therapeutics announced the closing of $2.75 million offering.</li>
<li>Aditxt, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares fell 19.7% to $1.86. Aditxt shares climbed around 46% on Wednesday after the company and Evofem amended and restated their merger agreement.</li>
<li>Locafy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCFY#NASDAQ">LCFY</a>) fell 19% to $5.33.</li>
<li>SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) fell 17.2% to $2.0850.</li>
<li>Torrid Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) fell 16.7% to $7.16 after Morgan Stanley downgraded the stock from Equal-Weight to Underweight and maintained its $5 price target.</li>
<li>Longeveron Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) declined 16.6% to $3.25. Longeveron announced a $9.0 million registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>Forestar Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOR#NYSE">FOR</a>) fell 13.9% to $30.99 after the company reported worse-than-expected third-quarter EPS and revenues.</li>
<li>Stardust Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) shares declined 13.3% to $21.22 after jumping around 145% on Wednesday.</li>
<li>Cetus Capital Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETU#NASDAQ">CETU</a>) shares declined 13.2% to $8.60 after surging 80% on Wednesday.</li>
<li>Meiwu Technology Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WNW#NASDAQ">WNW</a>) fell 13.2% to $1.11 after jumping more than 40% on Wednesday.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) fell 12% to $23.55.</li>
<li>American Rebel Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares fell 12% to $0.80 after jumping around 32% on Wednesday.</li>
<li>Beyond Meat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>) shares fell 9.4% to $6.49 following a report suggesting the company&#8217;s liquidity has weakened and it is engaging bondholders for debt discussions.</li>
<li>4D Molecular Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) declined 8.1% to $16.73. The company announced the presentation of Phase 2 PRISM interim data.</li>
<li>Texas Capital Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) fell 6.2% to $66.17 following downbeat quarterly results.</li>
<li>Nokia Oyj (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) fell 5.9% to $3.66 after the company reported mixed quarterly financial results.</li>
<li>Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) declined 5.4% to $37.85 as the company reported second-quarter 2024 total operating revenue growth of 2% year-over-year to $2.897 billion, missing the consensus of $2.945 billion.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39837919/podcastone-and-2-other-stocks-under-2-insiders-are-buying">PodcastOne And 2 Other Stocks Under $2 Insiders Are Buying</a></li>
</ul>

Intraday Update

Markets

ACXP

ADTX

AGEN

APVO

AREB

BYND

CETU

CHUY

COMM

CSIQ

CURV

FDMT

FTEL

INFY

JCSE

KOPN

LCFY

LESL

LGVN

LPSN

NKGN

ONCO

SDST

SILO

SPWR

TCBI

TCRT

VIRT

ZIMV

Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

AMETEK's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) short percent of float has fallen 34.26% since its last report. The company recently reported that it has 2.92 million shares sold short, which is 1.42% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.28 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>AMETEK Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721322920_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AMETEK has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AMETEK's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AMETEK's peer group average for short interest as a percentage of float is 11.31%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(AME) - Analyzing AMETEK's Short Interest

Watsco's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>) short percent of float has fallen 11.68% since its last report. The company recently reported that it has 3.07 million shares sold short, which is 10.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Watsco Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721322916_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Watsco has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Watsco's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Watsco's peer group average for short interest as a percentage of float is 3.92%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Dai-ichi Life Holdings

News

Latest news for Dai-ichi Life Holdings (OTC:DLICY) Stock